FAQ

MKC-1

An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2016
01219992016

Related topics

Related topics

2 relations
Microtubule Process

Narrower (1)

R440

Related mentions per year

Related mentions per year

1999-2016
1990200020102020
MKC-1
Microtubule Process
R440

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The Developtment of Creative Writing Model on Short Story Based Siri’ Na Pacce at the XI Class Senior High Schools in Makassar
The research was a development model in teaching of creative writing short story based siri’na pace. The purpose of this study… (More)
Is this relevant?
2014
2014
Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer
Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine-binding-protein (PEBP) family that modulates the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2012
Review
2012
mTOR inhibitors in breast cancer: a systematic review.
PI3K/AKT/mTOR pathway is a crucial mediator of tumor progression. As the PI3K/Akt pathway is heavily deregulated in breast cancer… (More)
Is this relevant?
2011
2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
Background MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • table 2
Is this relevant?
2010
2010
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
Background MKC-1 is an oral cell-cycle inhibitor with broad antitumor activity in preclinical models. Clinical studies… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2010
2010
The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent.
Bisindolylmaleimide MKC-1 (formerly known as Ro 31-7453) is a novel, orally active, small-molecule, cell cycle inhibitor with… (More)
Is this relevant?
2009
2009
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer.
5577 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity in xenograft models of human ovarian and… (More)
Is this relevant?
2009
2009
Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi… (More)
Is this relevant?
1999
1999
In vitro characteristics of early epidermal progenitors isolated from keratin 14 (K14)-deficient mice: insights into the role of keratin 17 in mouse keratinocytes.
Keratin 14 (K14) is believed to play a pivotal role in the maintenance of epidermal cell shape and contributing to their… (More)
Is this relevant?